In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief ...

Pfizer Inc.'s (PFE) decision to halt the development of its oral GLP-1 candidate due to a potential liver toxicity issue could pose tailwinds for smaller biotech rivals, according to Wall Street ...

Danuglipron was the latest drug investors were hinging hope on to enter the obesity market.

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new. Investigators from Mass General Brigham looked at claims data ...

The drugmaker said it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped the treatment.

It's probably safe to say that weight-loss drugs aren't going anywhere any time soon. According to the most recent data, six percent of American adults, or roughly 16 million people, take such ...